KEYTRUDA® (pembrolizumab) in first-line Head & Neck Squamous Cell Carcinoma

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.1

KEYTRUDA in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent HNSCC in adults whose tumours express PD-L1 with a CPS ≥ 1.1

Helping to redefine survival expectations for your first-line metastatic or unresectable recurrent (M/uR) HNSCC patients with PD-L1 expression CPS ≥11

For use in

First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).1

Patient

Suitable adults whose tumours express PD-L1 with a CPS ≥1.1

Testing

To prescribe KEYTRUDA, patients require timely validated PD-L1 testing, appropriate CPS evaluation and clinical considerations as per SmPC to inform treatment options.

Recommended Treatment approach as per SmPC

The recommended dose of KEYTRUDA in adults is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.1

Download the full presentation slides for the KEYNOTE-048 clinical study

KEYNOTE-048 was a randomised, open-label, Phase III study of pembrolizumab monotherapy vs EXTREME and pembrolizumab plus chemotherapy vs EXTREME in patients with untreated locally incurable recurrent or metastatic HNSCC.

KEYNOTE-048 Slide deck

Download (5.87MB)

Abbreviations

5-FU: 5 fluorouracil CPS: combined positive score
HNSCC: head and neck squamous cell carcinoma
M/uR: metastatic or unresectable recurrent
PD-L1: programmed death-ligand 1
QxW: x-weekly dosing

References

  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-OHN-00355 | Date of Preparation: September 2021